http://www.reportbuyer.com/rss.htmlFind comprehensive market research on Pharmaceutical Finance/Investment. Be the first to predict new opportunities and spot future trends. en-gbReportbuyerservice@reportbuyer.comenquiries@redwiredesign.comhttp://www.reportbuyer.com/pharma_healthcare/finance_investment/pharma_corporate_venture_capital_cvc_key_players_new_conditions_big_opportunities.htmlA good opportunity is opening up for pharma CVCs, but only if the corporate structure is right The medical/health and life science sector was the second highest corporate venture capital (CVC) investment sector in 2007/2008 with investment of US$959 million. Most big pharma companies have a CVC arm and they have been instrumental in securing key science and commercial assets. In May 2009, Lilly Ventures, the CVC arm of Eli Lilly, announced that it was to ""go it alone"". 7890efaeae5f5061626fc5cb66a59bccWed, 09 Sep 2009 12:00:00 GBPharma & Healthcare/Finance / Investmenthttp://www.reportbuyer.com/pharma_healthcare/finance_investment/investment_patterns_healthcare_industry_analysis.htmlThis research study examines the various investments that have happened in the healthcare industry over the years 2008-2009. The investments are broadly classified as Equity, Debt and Loans. The study analysis the trends in the investments, and also sub-classifies the investments by Time, Geography, Proceeds, Volume etc. 6f6a3b8c7a96801528bbf6eec8f1cbdeWed, 09 Sep 2009 12:00:00 GBPharma & Healthcare/Finance / Investmenthttp://www.reportbuyer.com/pharma_healthcare/finance_investment/biotech_financing_credit_crisis_strategies_radically_altered_landscape.html Since the financial meltdown, the relationship between Pharma and Biotech has been turned on its head. Previously, pharma companies had no choice but to license Biotech drugs at high prices in order to fill their sparse late stage pipelines. Overview licensing trends up until the credit crisis Strategic analysis of biotech's funding crisis Insight into how the biopharma market is expected to change and adapt Recommendations and potential financial solutions for biotech While Pharma is likely to prefer acquiring biotech targets out right, rather than navigating the road of complex licensing agreements, Datamonitor expects that licensing agreements will remain among Pharma and self sufficient biotech companies. f3c6390ecbed40c76fcba3a358bdf730Fri, 12 Dec 2008 12:00:00 GBPharma & Healthcare/Finance / Investmenthttp://www.reportbuyer.com/pharma_healthcare/finance_investment/divestment_strategies_pharma_divesting_order_grow.html Pharmaceutical companies are now divesting non-core assets such as medical devices and manufacturing plants in an effort to cut costs and focus on core strategies, primarily drug development. However, while some Pharma companies are narrowing their focus, targeting specific disease areas for future growth, others are taking a broader approach in an effort to spread risk and return on investment. Provides an introduction to divestment strategies in the current financial climate, including the drivers and resistors of divesting a company asset Offers recommendations on how the best divest to and how to optimize the divestment process Examines divesture deal trends and values during Q1 2006 to Q3 2008 Provides case study analysis of the divesture deal trends during Q1 2006 to Q3 2008 Most divesture decisions are made on a reactive basis when a company has no other choice, rather than proactively divesting a growing asset for a high price. 6232e5c05b6e18b3e47d7559e84f44e6Fri, 12 Dec 2008 12:00:00 GBPharma & Healthcare/Finance / Investmenthttp://www.reportbuyer.com/pharma_healthcare/finance_investment/life_sciences_funding_europe_2007.htmlLife Sciences Funding in Europe (2007) analyses the public, private and charity funding scenario in European Countries. Analysis of the Framework Programme 7 and other funding organisations in Europe has been provided. The countries included in the analysis are the United Kingdom, Germany, France, Italy and Spain. 80f2b6e11bb33711548506714a17dc24Mon, 03 Mar 2008 12:00:00 GBPharma & Healthcare/Finance / Investmenthttp://www.reportbuyer.com/pharma_healthcare/finance_investment/pharmaceutical_market_trends_2007_2011.html"The global pharmaceutical market grew to US$643 billion in 2006, growing at a compound annual growth rate (CAGR) of 10. 0% between 1999 and 2006. However, year-on-year growth slowed to 6. f84d4d7076b9ac98e2f32457a328c38bThu, 01 Nov 2007 12:00:00 GBPharma & Healthcare/Finance / Investmenthttp://www.reportbuyer.com/pharma_healthcare/finance_investment/pharmaceutical_cme.html Pharmaceutical CME departments struggle to measure performance for a number of reasons. The lack of hard measures for medical education, along with a fear of appearing non-compliant stops many companies from tracking return on investment (ROI). Many medical education departments use post-CME outcomes measures to judge the effectiveness of their investments in CME events. 0637186a1577ecdd8fad7b75e84bf458Fri, 01 Sep 2006 12:00:00 GBPharma & Healthcare/Finance / Investmenthttp://www.reportbuyer.com/pharma_healthcare/finance_investment/guide_venture_capital_european_biopharma.htmlIf you are managing a biopharma company, raising venture capital can be absolutely critical for the success of your company. The fund raising process should therefore be planned and carried out with the same level of seriousness and professionalism as any other serious business objective. This report is designed to speed up your VC raising campaign by distilling the information and knowledge you need to proceed efficiently. 0e27ee6724986cd27e44fcc94ecce8b2Thu, 09 Sep 2004 12:00:00 GBPharma & Healthcare/Finance / Investment